Compare · APP vs TEM
APP vs TEM
Side-by-side comparison of Applovin Corporation (APP) and Tempus AI Inc. (TEM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APP and TEM operate in Computer Software: Programming Data Processing (Technology), so they compete in similar markets.
- APP is the larger of the two at $206.17B, about 21.7x TEM ($9.48B).
- Over the past year, APP is up 52.7% and TEM is down 16.8% - APP leads by 69.5 points.
- TEM has been more active in the news (33 items in the past 4 weeks vs 11 for APP).
- Both have 25 recent analyst ratings on file.
PerformanceAPP+52.68%TEM-16.82%
2025-06-02+0.00%2026-06-01
- Company
- Applovin Corporation
- Tempus AI Inc.
- Price
- $613.73+0.12%
- $52.77+4.56%
- Market cap
- $206.17B
- $9.48B
- 1M return
- +37.51%
- -4.84%
- 1Y return
- +52.68%
- -16.82%
- Industry
- Computer Software: Programming Data Processing
- Computer Software: Programming Data Processing
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2024
- News (4w)
- 11
- 33
- Recent ratings
- 25
- 25
APP
Applovin Corporation
AppLovin Corporation engages in building a software-based platform for mobile app developers to enhance the marketing and monetization of their apps worldwide. The company's software solutions include AppDiscovery, a solution to automate, optimize, and manage user acquisition investments for business clients; and MAX, an in-app bidding solution that optimizes purchases of app ad inventory. Its business clients include various advertisers, internet platforms, and others. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Latest APP
- Chief Financial Officer (CFO) Stumpf Matthew sold $5,431,200 worth of shares (9,052 units at $600.00) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 177,450 units (SEC Form 4)
- AI Is Rewriting How Brands Reach Customers -- and How They Defend Themselves. This Small-Cap NASDAQ Stock Is Quietly Betting on Both
- Chief Technology Officer Shikin Vasily sold $1,412,419 worth of shares (2,889 units at $488.90) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Technology Officer Shikin Vasily sold $7,702,632 worth of shares (15,915 units at $483.99) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Technology Officer Shikin Vasily sold $34,346,828 worth of shares (70,916 units at $484.33) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 3,189,739 units (SEC Form 4)
- Principal Accounting Officer Dorosh Dmitriy covered exercise/tax liability with 331 shares, decreasing direct ownership by 0.30% to 111,213 units (SEC Form 4)
- CALO & Corp. Secretary Valenzuela Victoria covered exercise/tax liability with 2,730 shares, decreasing direct ownership by 1% to 263,961 units (SEC Form 4)
- Chief Financial Officer (CFO) Stumpf Matthew covered exercise/tax liability with 2,341 shares, decreasing direct ownership by 1% to 186,502 units (SEC Form 4)
- Chief Technology Officer Shikin Vasily covered exercise/tax liability with 2,730 shares, decreasing direct ownership by 0.08% to 3,252,543 units (SEC Form 4)
- CEO Foroughi Arash Adam covered exercise/tax liability with 2,730 shares, decreasing direct ownership by 0.11% to 2,427,684 units (SEC Form 4)
Latest TEM
- Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xH
- Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development
- Tempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research Community
- Tempus Introduces 'Preview': Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results
- CEO and Chairman Lefkofsky Eric P sold $7,763,312 worth of shares (166,250 units at $46.70) as part of a pre-agreed trading plan (SEC Form 4)
- Tempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in Oncology
- Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor Portfolio
- Tempus Expands Next Platform to Deliver Real-Time Clinical Intelligence and Close Critical Care Gaps Across Oncology
- SEC Form 144 filed by Tempus AI Inc.
- Tempus Upgrades Its Smart Physician Platform, Hub, with Next-Generation Agentic AI Architecture to Streamline Clinical Workflows